In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...
Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...
Eisai will request a reconsideration of this initial decision under Section 60 of the Therapeutic Goods Act within 90 days to make lecanemab available for eligible people living with early AD in ...
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a ...
The Therapeutic Goods Administration (TGA) has made the decision not to register lecanemab (LEQEMBI) for the treatment of ...
A much-anticipated drug that holds the promise of delaying symptoms of Alzheimer’s disease will not be available in Australia ...
Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.
New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
An estimated $133 million to $336 million worth of lecanemab may be discarded every year. Adding a 75-mg vial could save ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback